Lonza reports softer performance in Q1 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
EBITDA before special items falls 1.3 percent to € 4.41 billion
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Lupin updates on shipment of Mirabegron ER Tablets
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Subscribe To Our Newsletter & Stay Updated